Chad P. Bown

Chad P. Bown is Reginald Jones Senior Fellow at the Peterson Institute for International Economics in Washington. Bown previously served as senior economist for international trade and investment in the White House on the Council of Economic Advisers and most recently as a lead economist at the World Bank, conducting research and advising developing country governments on international trade policy for seven years. Bown was a tenured professor of economics at Brandeis University, where he held a joint appointment in the Department of Economics and International Business School for 12 years. He has also spent a year in residence as a visiting scholar in economic research at the World Trade Organization (WTO) Secretariat in Geneva. Bown received a BA magna cum laude in economics and international relations from Bucknell University and a PhD in economics from the University of Wisconsin-Madison.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More